Diagnosis and assessment of pulmonary arterial hypertension

…, JE Loyd, A Manes, M McGoon, R Naeije… - Journal of the American …, 2009 - jacc.org
Naeije has received research grant support from Actelion, Encysive, and Pfizer; and has
served as a consultant and/or steering committee member for Actelion, Encysive, Lung Rx, …

Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology

…, PR Forfia, SM Kawut, J Lumens, R Naeije… - Journal of the American …, 2013 - jacc.org
Survival in patients with pulmonary arterial hypertension (PAH) is closely related to right
ventricular (RV) function. Although pulmonary load is an important determinant of RV systolic …

Pulmonary hypertension in COPD

A Chaouat, R Naeije… - European Respiratory …, 2008 - Eur Respiratory Soc
Mild-to-moderate pulmonary hypertension is a common complication of chronic obstructive
pulmonary disease (COPD); such a complication is associated with increased risks of …

[HTML][HTML] Inhaled iloprost for severe pulmonary hypertension

…, R Naeije, LJ Rubin, S Nikkho, R Speich… - … England Journal of …, 2002 - Mass Medical Soc
Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo …

G Simonneau, RJ Barst, N Galie, R Naeije… - American journal of …, 2002 - atsjournals.org
Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous
prostacyclin has proven to be effective. However, this treatment requires a permanent …

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

…, A Frost, EC Lawrence, S Shapiro, R Naeije… - Journal of the American …, 2006 - jacc.org
Objectives : We sought to determine the optimal dose of the selective endothelin A (ET A )
receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for …

Ambrisentan therapy for pulmonary arterial hypertension

…, AM Keogh, AE Frost, D Zwicke, R Naeije… - Journal of the American …, 2005 - jacc.org
Objectives : The purpose of this study was to examine the efficacy and safety of four doses
of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with …

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

…, O Sitbon, A Torbicki, M Delcroix, R Naeije… - Journal of the American …, 2002 - jacc.org
Objectives : The purpose of this study was to assess the efficacy and safety of beraprost
sodium, an orally active prostacyclin analogue, in New York Heart Association (NYHA) …

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

…, IM Lang, A Manes, FJ Martinez, R Naeije… - Journal of the American …, 2009 - jacc.org
… and lung function was weak (FEV 1 , r 2 = 0.11 and Pao 2 , r 2 = 0.03). The mPAP was more
closely related to pulmonary capillary wedge pressure (PCWP) (r 2 = 0.32), which was mildly …

Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis

…, F Ferrara, A Cittadini, M Rubenfire, R Naeije - Journal of the American …, 2013 - Elsevier
… right atrial pressure (RAP).9, 10, 11, 12 Several studies have shown modest to good correlations
between estimated RV systolic pressure and invasively measured pressures (R = 0.57–…